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ABSTRACT
U.S. citizens depend extensively on medicines for health and
quality of life. Yet a major problem attends the drug supply: counter-
feit medicines. Although currently the United States has a relatively
safe, closed system, it has not been immune to counterfeits, and harm
associated with counterfeits has occurred here. Further, because ter-
rorist activities have been connected to counterfeit production, and
perverse legal incentives only lightly punish drug counterfeiting, ter-
rorists and drug lords have shifted production to this highly lucrative,
but less expensive and lower risk, activity. In addition, through sec-
ondary wholesaler and provider purchase and sale of drugs in the
"gray market," U.S. drugs may pass through many hands before fi-
nally reaching the consumer. This process has allowed fake drugs to
enter the supply chain and harm consumers. Similarly, Internet drug
purchases also are a source of counterfeit drug importation that harms
unsuspecting patients. Broad scale importation may result in opening
the U.S. domestic gray market to scrupulous and unscrupulous suppli-
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ers from all over the world and, as has happened in other countries,
may significantly increase the number of fakes introduced into in-
gested medicines. Public policy should ensure that safe, affordable
drugs be the goal, with safety as the emphasis. Consumers should use
available tools to protect themselves against harm associated with
counterfeit drugs.
INTRODUCTION
Americans rely extensively upon prescription medications to
maintain health and quality of life. According to the National Center
for Health Statistics, in 2002 at least 1.3 billion drugs were prescribed
to patients in physician offices, 196 million in U.S. emergency de-
partments, and 139 million in outpatient settings.' Almost two-thirds
of visits to physician offices and hospital outpatient departments had
at least one drug associated with the visit, and 7% of visits had five or
more drugs. 2 In 2004, over 3.5 billion prescription drugs were dis-
pensed by U.S. pharmacies to patients. Estimates indicate that annual
expenditures for prescription drugs in the United States top $230 bil-
lion each year,4 and there is every indication that these numbers will
only increase.
In the United States, prescription drug use is ubiquitous. At least
44% of all citizens report using prescription drugs in the last month,
and indeed, 17% reported using at least three or more.5 Seniors use a
large portion of these medicines. Greater than 80% of seniors use at
least one drug, 50% report taking at least three prescription drugs, and
at least 20% of seniors take at least five prescription medications. 6 Al-
though seniors account for only 13% of the population, as patients
they account for more than one-third of all prescriptions, and as payers
they account for more than 40% of each dollar spent on drugs each
1. NATIONAL CENTER FOR HEALTH STATISTICS, THERAPEUTIC DRUG USE, http://www.
cdc.gov/nchs/fastats/drugs.htm (last visited Aug. 16, 2005).
2. Id.
3. IMS HEALTH, U.S. PRESCRIPTION ACTIVITY BY CHANNEL, 2004 (Jan. 2005),
http://www.imshealth.comlims/portal/frontlarticleC/0,2777,6599_49695974_6891355 1,00.ht
ml.
4. IMS HEALTH, U.S. PURCHASE ACTIVITY BY CHANNEL, 2004 (Feb. 2005),
http://www.imshealth.con/ims/portal/front/articleC/0,2777 ,6599_49695983_69891354,00.ht
ml.
5. NAT'L CTR. FOR HEALTH STATISTICS, U.S. DEP'T OF HEALTH & HUMAN SERVS.,
HEALTH: UNITED STATES: 2004, at 50-54 (2004), available at http://www.cdc.gov/nchs/
data/hus/hus04trend.pdf.
6. Id.
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year. 7 It is estimated that seniors alone will spend more than $70 bil-
lion on prescription medicines in 2005.8
The advent of prescription medications has become a powerful
tool in the medical arsenal against disease and in promotion of health
and quality of life. Yet the success of prescription drugs, and their ex-
tensive use, has attracted unsavory characters interested in exploiting
vulnerable patients and the market for medicines. These creatures in-
troduce and peddle counterfeit drugs through vulnerabilities in the
drug distribution system. In the United States, counterfeits are a
growing problem, but our domestic, closed system has so far main-
tained a high level of safety. 9 However, the rest of the world has ex-
perienced, and does experience, the problem with fake medicines due
to extensive movement of drugs in and out of countries through licit
and illicit importation.'" Hence, without extensive safety measures,
allowing large-scale importation of drugs into the United States may
import the problems of other countries into this one.
THE PROBLEM: COUNTERFEITS
Counterfeit drugs are a worldwide problem. The World Health
Organization (WHO) reported that a significant portion of the world's
drug supply is counterfeit. The scope of the problem is unknown;
however, WHO estimates that up to 60% of drugs in some developing
countries are fake, and up to 20% are fake in some developed coun-
tries.'1 Overall, approximately 10% of all drugs sold in the world are
counterfeit. 2 Through importation and reimportation, fake drugs en-
7. FAMILIES USA, COST OVERDOSE: GROWTH OF DRUG SPENDING FOR THE ELDERLY,
1992-2010, at 2 (2000), available at http://www.famailiesusa.org/site/DocServer/drugod.
pdfdoclD=726.
8. Id. at 4. Since these estimates were performed in 2000, it is likely the cost will be
even higher.
9. U.S. DEP'T OF HEALTH & HUMAN SERVS., HHS TASK FORCE ON DRUG IMPORTATION:
REPORT ON PRESCRIPTION DRUG IMPORTATION 37-38 (2004), available at http://www.hhs.gov/
importtaskforce/Report I220.pdf [hereinafter HHS TASK FORCE].
10. See, e.g., Albert Wertheimer et al., Counterfeit Pharmaceuticals: Current Status
and Future Projections, 43 J. AM. PHARMACISTS ASS'N 710 (2003); Paul M. Rudolf & Ilisa
B.G. Bernstein, Counterfeit Drugs, 350 NEW ENG. J. MED. 1384 (2004); Liza Gibson, Drug
Regulators Study Global Treaty To Tackle Counterfeit Drugs, 328 BRIT. MED. J. 486 (2004);
Helen Frankish, WHO Steps Up Campaign on Counterfeit Drugs, 362 LANCET 1730 (2003);
INT'L COUNCIL OF NURSES, NURSES FOR PATIENT SAFETY: TARGETING COUNTERFEIT AND
SUBSTANDARD MEDICINES (2005), available at http://www.icn.ch/indkit2005.pdf.
11. World Health Org. [WHO], Fact Sheet No. 275: Substandard and Counterfeit Medi-
cines (2003), http:www.who.int/mediacentre/factsheets/2003/fs275/en [hereinafter Fact Sheet
No. 275].
12. Id.
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ter into country supplies and end up in drugstores, and, ultimately, in
patients who ingest or are injected with them. 13
Although the United States has not experienced the relative de-
gree of counterfeits that other countries have, it has not been immune.
For example, in 2003, 200,000 bottles of Lipitor, a cholesterol drug
and one of the world's best selling medicines, were recalled due to the
discovery that they were counterfeit."4 In the summer of 2003, blitz
inspections by government officials of foreign drug imports at U.S. in-
ternational mail facilities found that 88% were unapproved, may have
been stored inappropriately, and had safety issues. 5 In 2004, U.S.
Food and Drug Administration (FDA) officials discovered Mexican
drugs imported by U.S. citizens were fake; 6 and in May 2005, the
FDA issued warnings on fake Lipitor, Viagra, and an unapproved os-
teoporosis drug being imported over the Mexican border by U.S. citi-
zens. 
17
Increasing evidence regarding the problem of counterfeit drugs in
this country has been piling up. The U.S. Department of Health and
Human Services has investigated the issue and in December 2004 is-
sued its report detailing significant security issues associated with
drug importation and counterfeit drugs. 8 Notably, there are only 16.9
full-time FDA employees responsible for covering all international
mail facilities in the United States to detect incoming counterfeit
drugs-and that is not their only duty."' With 10,000,000 packages of
imported prescription drug products entering the United States each
year, it is highly unlikely that the resources devoted to detecting prob-
lematic drugs are anywhere near adequate. As well, a story in Busi-
ness Week in 'February 2005 noted the tremendous increase and mar-
ket in counterfeit goods worldwide, including counterfeit medicines.2"
Further, the Pharmaceutical Security Institute, a nonprofit trade asso-
13. See WHO, Essential Drugs and Medicines Policy (2005),
http://www.who.int/medicines/organiztion/qsm/activities/qualityassurance/cft/CounterfeitOve
rview.htm.
14. See FDA Kicks Off Crackdown on Rising Rate of Counterfeit Drugs: Recalls of Bot-
tles of Fake Lipitor Highlights Problem Infecting Nation's Medicine Supply, CHARLESTON
POST & COURIER, July 17, 2003.
15. HHS TASK FORCE,,supra note 9, at 13.
16. FDA, FDA WARNS CONSUMERS ABOUT COUNTERFEIT DRUGS PURCHASED IN MEXICO
(2004), http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01303.html.
17. FDA, FDA WARNS CONSUMERS ABOUT COUNTERFEIT DRUGS PURCHASED IN
MEXICO (2005), http://www.fda.gov/bbsltopics/ANSWERS/20O5/ANS01357.html.
18. HHS TASK FORCE, supra note 9.
19. HHS TASK FORCE, supra note 9, at 56 fig. 5.3.
20. See Frederik Balfour, Fakes!, Bus. WK., Feb. 7, 2005, at 54, available at
http:/fbusinessweek.com/magazine/content/05_06/b3919001_mzOOl .htm.
4
California Western International Law Journal, Vol. 36, No. 1 [2005], Art. 3
https://scholarlycommons.law.cwsl.edu/cwilj/vol36/iss1/3
2005] UNDERSTANDING IMPORTATION AND COUNTERFEIT DRUGS 11
ciation group, reported in May 2005 that problems in counterfeiting,
theft, and drug diversion were greatest in the United States for a sec-
ond year in a row.'
The FDA guesses that approximately 1% or less of drugs in the
United States are tainted or counterfeit.22 Assuming only 0.1% of
drugs in the United States are affected, in combination with the WHO
estimates, this means that approximately 3,500,000 to 350,000,000
prescriptions may be potentially affected by counterfeit drugs each
year.
What Kinds?
When counterfeit drugs first started being detected, most fell into
the category of lifestyle drugs, for example, Viagra. In some quarters,
there was very little sympathy for these victims because of the "de-
signer" and "lifestyle" nature of these drugs. However, recent discov-
eries include AIDS/HIV therapy, over-the-counter pain medications,
antibiotics, insulin, cholesterol drugs, hormone replacement therapy,
flu medications, cancer drugs, anti-arthritis drugs, cardiac drugs, anti-
parasitic drugs, antihistamines, and many more. 3 The counterfeit
market has matured: it has gone from lifestyle drugs to lifesaving
drugs. It is likely that all citizens are potentially affected now.
Harm occurs in three ways. If the fake drug contains the wrong
drug, the patient is not treated for the disease he or she has. This can
occur when, for example, vials (in some cases purchased on online
auction sites like Ebay24) are relabeled with a fake label as another,
more expensive, antibiotic with different bacterial coverage than the
one the physician prescribed. This not only does not help the patient
get better, but also contributes to the increase in antibiotic resistance
of bacterial pathogens, making infections harder to fight.
21. Julie Appleby, Stolen, Counterfeit Drug Problems Rise, USA TODAY, May 10,
2005, available at http://www.usatoday.com/news/health/2005-05-10-counterfeit-drugs-
usatx.htm.
22. Rudolf & Bernstein, supra note 10.
23. Robert Cockbum et al., The Global Threat of Counterfeit Drugs: Why Industry and
Governments Must Communicate the Dangers, 2 PLOS MEDICINE 302, 304-06 (2005), avail-
able at http://medicine.plosjournals.org/archive/1 549-1676/2/41pdf/10. 137 ]-journal.
pmed.0020100-S.pdf.
24. LEw KONTNIK, PHARMACEUTICAL COUNTERFEITING: PREVENTING THE PERFECT
CRIME 2 (2004), http://www.fffenterprises.com/web-files/fff_whtpprl 11804.pdf. Note that
pharmaceutical manufacturing and labeling equipment is also available on Ebay. See, e.g.,
GLOBAL OPTIONS INC., AN ANALYSIS OF TERRORIST THREATS TO THE AMERICAN MEDICINE
SUPPLY 29-30 (2003), available at httpJ/www.globaloptions.com/booktext2003.pdf.
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The patient may also get the wrong concentration or dose with a
counterfeit. This has occurred with Botox treatments, where a physi-
cian was supplied with a research version of Botox, which is much
more concentrated than that utilized for anti-wrinkle treatment and not
intended for human use. It resulted in respiratory paralysis and near
death for several patients, including the physician, who was using it
himself.25  Another example was a cancer patient who needed
Erythropoietin, which virtually all patients require after chemotherapy
because of the latter's side effect of causing severe anemia. Criminals
sold a form of the IV drug diluted with bacterially-contaminated wa-
ter, which was intended to be injected directly into the patient.26
The third common method of harm is when the fake drug has no
active ingredients. Patients are once again harmed by not being
treated, but also harmed by materials used to make the fake drug.
This includes bacteria-laced water as IV antibiotics, toxic yellow road
paint with floor wax and boric acid27 (the latter used commonly to kill
cockroaches) as an analgesic, and, horrifyingly, antifreeze used to
make counterfeit cough syrup. The latter has been documented as
killing over 100 children before it was discovered.28
Why?
The answer is easy: money. WHO and the FDA estimate that
worldwide sales of counterfeit drugs represent between $32 billion
and $35 billion annually; 29 that is $88 million to $96 million in sales
each day. Related to this incredible cash flow, the FDA and interna-
tional government authorities warn that counterfeit drug sales are
linked to funding terrorist activities, including those of Hezbollah and
25. See, e.g., Press Release, U.S. Dep't of Justice, Professor of Ophthalmology/Director
of Oculo-Facial Plastic Surgery at University of Kentucky Charged in Fake Botox Prosecu-
tion (Mar. 22, 2005), available at http:llwww.usdoj.gov/usaolfls/BakerRobertMD.html.
26. Catherine Wilson, Two Florida Men Sentenced for Drug Scam, AEGIS, Aug. 29,
2003, http://www.aegis.comnews/ap/2003/AP030846.html.
27. Continuing Concerns Over Imported Pharmaceuticals: Hearing Before the Sub-
comm. on Oversight and Investigations of the H. Comm. on Energy and Commerce, 107th
Cong. (2001) (prepared witness testimony of James Christian, Vice-President and Head of
Corporate Security, Novartis International AG), available at http://energycommerce.house.
gov/107/hearings/06072001 Hearing267/Christian404print.htm.
28. Fact Sheet No. 275, supra note 11.
29. Id.; Robert Cockburn et al., supra note 23, at 302.
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Al Quaeda.3 ° The FDA has also identified the drug supply as a target
for terrorists. 3'
It is also easy to produce these drugs. Making illicit drugs such as
heroin and cocaine is a very difficult, expensive, and highly risky ac-
tivity. Counterfeit licit drugs on the other hand, are cheap: nefarious
producers need only make drugs that appear authentic; they do not
have to actually work. And it is financially lucrative: a fake pill may
cost less than $0.01 to make, but can be sold for $0.30,32 which is still
cheaper than the actual drug. And, production can be done by un-
skilled workers.
Another interesting reason why criminals are turning to counter-
feit production is related to pressure from the United States and do-
mestic country governments with illicit drug production. In Latin
American countries where a significant amount of cocaine and heroin
production occurs, these governments have cracked down on these ac-
tivities by passing laws that severely punish drug lords for illicit
manufacturing. Hence, such production may result in ten to fifteen
years in prison.33 Yet for production of fake licit drugs, penalties may
be only six months in jail, and individuals caught can be out on bail in
just a few days.34 Therefore, in an unintended consequence of appro-
priate penalties for drug lords caught making illegal drugs, a business
reevaluation has shifted production to a much cheaper, less risky, and
more lucrative product: counterfeit drugs.
A tremendous part of this problem domestically in this country
also results from the "gray market." Traditionally, 90% of prescrip-
tion drugs move from the manufacturer to large wholesalers, then di-
rect to the pharmacies in the community or other facilities such as
hospitals and nursing homes. Three large bulk wholesalers dominate
this market. However, up to 10% of drugs pass through the gray mar-
30. GLOBAL OPTIONS INC., supra note 24, at 13-14, 69-70, 159-65.
31. Associated Press, FDA: AI-Qaida Could Poison Medicines, MSNBC.coM, Aug. 12,
2004, http://msnbc.msn.com/id/5682351; Fake Drugs Are Real Dangers for U.S. Consumers,
PR NEWSWIRE, Aug. 13, 2004, http://www.pmewswire.com/cgi-bin/stories.pl?ACCT=109&
STORY=/www/story/08-13-2004/0002231340&EDATE=.
32. Kerry Capell & Suzanne Timmons, What's in that Pill? In Latin America, Fake
Drugs Are as Lucrative as Cocaine, Bus. WK., June 18, 2001, available at
http://www.businessweek.com/magazine/content/01_25/b3737153.htm.
33. Id.
34. Id.
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ket, represented by thousands of interactions between larger and
smaller wholesalers and providers.35
Theoretically, bulk wholesalers sell direct to customers like con-
sumer and hospital pharmacies, who then dispense these drugs to pa-
tients. However, in reality, the "Big Three" wholesalers sometimes
buy back drugs to cover short term shortages, while pharmacies and
others sell stock when they need cash flow. Excess supplies with im-
pending expirations are sold, bulk drugs are sold to repackagers to
create consumer-level sales products, and arbitrage activities result in
prescription medicines passing through many hands before reaching
the final seller and the patient. This gray market allows tainted and
fake drugs to enter the distribution chain, and ultimately, the patient.36
Although counterfeit/gray market problems are not well known
here, they are internationally. This is due in part to problems with
parallel trade, i.e., international drug importation, in Europe and other
countries around the world, where drugs may pass through many dif-
ferent countries and scrupulous and nonscrupulous sellers before end-
ing up in a pharmacy.37 The problem is similar to issues associated
with, for example, buying used cars being sold by rental car compa-
nies. You may like and trust the person who is selling you the car, but
do you trust that all the renters/users of the car did not abuse it, that
the car was appropriately maintained, and that there are no hidden ac-
cidents or faults? You may trust the representative who is selling you
drugs across the counter, but do you trust all the other persons who
have handled the medicine to be trustworthy, to have stored the drugs
in appropriate conditions, and to have verified their authenticity? Be-
cause importation may extend the gray market outside our closed sys-
tem to worldwide suppliers, the counterfeits problem the world ex-
periences may become our own.
35. Laura Willard, Allocating Responsibility for Counterfeit Prescription Drugs, 8 J.
BIOLAW & Bus. 41 (2005); Bette Hileman, Counterfeit Drugs, CHEMICAL & ENGINEERING
NEWS, Nov. 10, 2003, at 36; GLOBAL OPTIONS, supra note 30, at 21-22.
36. KONTNIK, supra note 24, at 5-6. Some entities have indicated they will no longer
accept drugs from wholesalers who use middlemen. See Jenn Abelsen, CVS Takes Step to
Keep Fake Drugs Off Shelves; Firm Tightens Criteria for Picking Suppliers, BOSTON GLOBE,
May 25, 2005, available at http://www.boston.com/business/articles/2005
/05/25/cvstakes.step-tokeepfake-drugs-offshelves.
37. KONTNIK, supra note 24, at 4 fig.4; WHO, supra note 13. Europe has had similar
problems with foodstuffs, which represent very much the same dynamic. For example, both
Switzerland and Ireland have reported illegally imported foods that are linked to organized
crime and unsafe product conditions. See, e.g., Adam Beaumont, Illegal Meat Trade Sparks
Health Fears, NZZ ONLINE, May 23, 2005, http://www.nzz.ch/2005/05/23/eng/ arti-
cle5799697.html; Illegal Food Import Seizures Rise, BBC NEWS, May 25, 2005, available at
httpJ/news.bbc.co.uk/2/hi/uk-news/northern_ireland/ 4579099.stm.
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LAW AND THE INTERNET
Importation of medicines is not legal at the current time.38 But the
counterfeit/gray market concern is, nevertheless, a growing problem.
This is because importation is occurring through Internet pharmacy
purchases. It is estimated that the United States spends $1 billion on
Internet pharmacy purchases each year, and that number is increas-
ing. 39
Although Web sites may display Canadian or U.S. flags, they may
or may not be located in these countries, and clearly there is a question
as to whether drugs that are being sold are actually from these coun-
tries. One key legal concern: drug shipments through countries like
38. According to a letter written by Randall W. Lutter of the FDA,
virtually all prescription drugs imported for personal use into the United
States... violate the [Federal Food, Drug, and Cosmetics Act (FFDCA)] because
they are either unapproved new drugs (21 U.S.C. § 355), labeled incorrectly (21
U.S.C. §§ 352, 353), or dispensed without a valid prescription (21 U.S.C. §
353(b)(1)). Importing a drug into the United States that is unapproved and/or does
not comply with the labeling requirements in the FFDCA is prohibited under 21
U.S.C. §§ 331(d), and/or (a). See also 21 U.S.C. § 381(a).
FDA approvals are manufacturer-specific, product-specific, and include many re-
quirements relating to the product, such as manufacturing location, formulation,
source and specifications of active ingredients, processing methods, manufacturing
controls, packaging location, container/closure system, and appearance. 21 C.F.R.
§ 314.50. Generally, drugs sold outside of the United States are not manufactured
or packaged by a firm that has FDA approval for that drug. Moreover, even if the
manufacturer has FDA approval for a drug, the version produced for foreign mar-
kets usually does not meet all of the requirements of the United States approval,
and thus is unapproved. 21 U.S.C. § 355. The version also may be misbranded
because it may lack certain information that is required under 21 U.S.C. §§ 352 or
353(b) but is not required in the foreign country, or it may be labeled in a language
other than English (see 21 C.F.R. § 201.15(c)).
Second, with respect to "American goods returned," it is illegal for any person
other than the original manufacturer of a drug to import into the United States a
prescription drug that was originally manufactured in the United States and sent
abroad (21 U.S.C. § 381(d)(1)). This is true even if the drug at issue were to com-
ply in all other respects with the FFDCA. Importing a drug into the United States
in violation of section 381(d)(1) is prohibited under 21 U.S.C. § 331(t).
Thus, to ensure compliance with the FFDCA, any person that intends to import
prescription drugs into the United States must ensure, among other things, that it
only imports FDA-approved drugs that comply with their FDA approvals in all re-
spects, including manufacturing location, formulation, source and specifications of
active ingredients, processing methods, manufacturing controls, container/closure
system, and appearance. 21 C.F.R. § 314.50. The importer must also ensure that
each drug meets all applicable U.S. labeling requirements, and that such drugs are
not imported in violation of the "American goods returned" provision in 21 U.S.C.
§ 381(d)(1).
Letter from Randall W. Lutter, Ph.D., Assoc. Comm'r for Policy and Planning, FDA, to
Kenny Guinn, Governor of Nevada (May 20, 2005), available at http://www.fda.gov/
oc/opacom/hottopics/importdrugsguinnO52005.html.
39. Julie Appleby, Canada's Cheap Drugs Not the Answer, USA TODAY, Aug. 28,
2003, available at http://www.usatoday.com/tech/news/2003-08-27-canadadrugsx.htm.
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Canada and western Europe are not subject to those countries' health
safety laws if the products are not earmarked for domestic consump-
tion.' Therefore, drugs from India and China, for example, if only
passing through Canada en route to U.S. citizens, are not subject to
Health Canada safety rules. This legal reality puts in stark relief how
international counterfeit/gray market implications can arrive in our
very mailboxes and homes.
In addition, the law has had tremendous difficulties in protecting
consumers from counterfeits. Consumers cheated and harmed by
rogue Internet pharmacies that sell tainted drugs have little recourse
against these offshore facilities, which may simply sprout again in an-
other form, even assuming the site is closed. As well, penalties in the
United States are weak: for example, counterfeiting a trademark may
get the perpetrator ten years in jail, but counterfeiting a drug subjects
him or her to only up to three years in prison.41 Such perverse incen-
tives are akin to the effects of Latin American legal systems that only
lightly punish counterfeit drug production.
REFORM
Drugs must be authentic and safe to provide the benefits of im-
proved life. But counterfeits are cheating patients of that benefit and
possibly exposing them to harmful agents. Weaknesses of the drug
distribution and legal systems should be addressed to protect patients
from harm. Internet pharmacies and importation efforts should be
closely scrutinized to ensure we err on the side of safety to limit the
international gray markets and unscrupulous individuals preying on
the ill. It bears emphasizing that we need safe, affordable drugs, and
safety must come first. Penalties for producing and selling counterfeit
drugs should be made at least as severe as producing and selling co-
caine and heroin. Law enforcement, providers, and public health and
safety agencies internationally should cooperate and establish opera-
tions and reporting infrastructures focusing on this huge international
industry and problem. Furthermore, technological standardization and
40. See, e.g., WHO, supra note 13; Christine Clark, British Pharmaceutical Conference
2003: Counterfeiting, 271 PHARMACEUTICAL J. 453, 454 (2003). "The Government of Canada
has never stated that it would be responsible for the safety and quality of prescription drugs
exported from Canada into the United States, or any other country for that matter." Diane
Gorman, Health Canada Assistant Deputy Minister, Letter to the Editor, WASH. POST, May 9,
2003.
41. FDA, Protecting Consumers from Counterfeit Drugs, FDA CONSUMER, May-June
2004, available at http://www.fda.gov/fdac/features/2004/304_drug.html.
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implementation of methods such as radio frequency ID tags, holo-
grams, and other methods should be supported to stay ahead of coun-
terfeiters to ensure appropriate pedigree and identification of valid
drugs.
Patients should also realize that they are the last barrier to harm
from these fakes. Using the safety checklist SAFE DRUG,42 available
at the Partnership for Safe Medicines Web site,43 can reduce the
chances of harm from counterfeit medications. It focuses upon using
Samples to determine baseline responses and information about drugs,
checking Appearance of the drug each time it is taken, noting the Feel
and taste of the drug at each administration while recording it down in
a medication diary, and Evaluating the drug with respect to feel, taste,
and medium term response. If a problem is suspected, call your Doc-
tor-have a low threshold of suspicion, and use this article as an ex-
cuse if you need one! Then Report the drug to the relevant authorities
(e.g., the FDA, law enforcement, manufacturer, local pharmacy where
purchased). Make the drug Unavailable by taking it out of your medi-
cine cabinet, taping the top shut, and marking it with an X in red so it
will not be confused with legitimate drugs. Finally, Give details of
your experience by collecting all the materials (e.g., packaging, pack-
age insert, remaining pills) and outlining your experience to law en-
forcement and others to allow thorough investigations to occur, so that
others will be protected by it.
CONCLUSION
In the medical world, there is a standard saying on the wards: the
chances may be one in a thousand, but when it happens to you, it's
100%. There is no greater place this applies than in the venue of pre-
scription drugs. No financial or legal remedy will replace the life lost
or the physical and emotional suffering experienced because of a fake
drug. This reality must be remembered when designing our legal sys-
tems and processes to thwart those who would prey upon the innocent,
vulnerable patient.
42. The full SAFE DRUG safety checklist is included in the Appendix. Such a check-
list may become more of the consumer culture. See, e.g., Don Oldenburg, Consummate Con-
sumer: Raising the Alarm on Rise in Counterfeit Drugs, WASH. POST, Apr. 5, 2005, at C9
(discussing the SAFE DRUG checklist in the context of counterfeit drug information).
43. Partnership for Safe Medicines, An 8-Step Check List for Medicine Safety,
http://www..safemedicines.org/resources/safedrug.pdf (last visited Aug. 16, 2005).
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Appendix
An 8-Step Check List for Medicine Safety
The Partnership for SAFE MEDICINES
l(SAFEMEDICINES.org
S.A.F.E. D.R.U.
is a "how-to" guide t
help consumers identif
and protect agains
counterfeit medicines
This eight-step chec
list helps consumer
judge whether thei
medications are saf
and provides tips o
what to do ifa drug ha
been compromisec
The Partnership for Safe
ledicines is committed to
helping consumers assure that
the prescription drugs they are
taking ate safe and effective.
The SAFE DRUG. guide
was orgially devtoped by
Bryan A Liang. MD, PhD, JD of
the Institute of Health Law
Studies, California Western
School of Law md the San
Diego Center for Patient Safety,
UCSD School of Medicine, and
relied witi the NPitnership tor
Safe Medwiries.
3 SampIe: Request samples of your medications from your physician when first
having at medication prescribed in order to compare the appearance, taste, texture,
and reaction later to medications filled through the doctor's prescription.
M anufacturer samples are usually only available for brand name medications and
not generics. When available, samples will help patients establish a "baseline" of
pruct characteristics. Save the sample's packaging fir lture comparison. If using
the Internet to purchase drugs, make sure the Web site is a "VIPPS" certified site.
k For a listing of approved sites, see: www.nabp.net/vpps/consumer/listall.asp.
Please note that genetics may differ in shape or color and still be a safe and effective
product. For specific questions on identification of medications, talk to your
r phamacist.
e Appearance: Compare the prescription medicine you receive with what it is
fl supposed to look like by taking pictures of the original manufacturer's drug and all
S associated packaging. You can also find pictures in the Physicians Desk Reference
available at your local library. When comparing packaging, look for differences in
paper, printing (is it the same size, raised print, embossed, etc.), color, and fonts.
Feel: Take note of the prescription drug's taste and any associated feeling once
you take it. For example, if injecting a medication, is it supposed to bum? Is there
anything unusual in your body's reaction compared to previous experiences?
Evaluate: How is your body reacting over the course of treatment? Do you feel
that you are benefiting from the medication? Is your condition improving,
stabilizing, or reverting back to ill health? Ask your doctor or pharmacist what you
should expect to feel and when you should expect to begin feeling relief or
improvement. Remember: counterfeit drugs can contain no active ingredient, not
enough, or too much.
Doctor. If your drugs do not seem to have the same taste or if you feel different
than usual, immediately write down your symptoms and contact your doctor and
phamacist.
Report: If you have any concerns about your drugs, or have confirmed there is a
difference in packaging, labeling, or pills, you should itmnediately contact the
phammacy where you purchased them. You may also want to contact the FDA and
the manufacturer of the medication to report your concerns. The FDA can be
contacted by calling toll-free 1-800-FDA-1088 (800-332-1088), or on the Web at
www.fda.gov/medwatch.
Unavailable: If you confirm that your medicine has been compromised,
immediately remove it from your medicine cabinet, mark the packaging with a red
pen, and put tape around the top of the drug container so that it will be unavailable
to you or others in your family. It is important that you and any fansily members do
not confuse this medication with any legitimate prescription drugs you may be
taking. Take the medications to your local law einforcement officials or contact the
FDA for more information.
Gathen Gather all the information you can find related to how you got the
counterfeit medication and how lonF you have been taking it. One of the key issues
is where you purchased the medicaton. Was it from the Internet, from a mail
order, or from a local pharmacy? When did you purchase the medication? Do you
still have the packaging? How long have you been taking the counterfeit drugs? If
the medication must be taken routinely, you should also contact your physician or
pharmacist to arrange for a new supply so that you can resume taking your
medication.
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